Accurate assessment of the p53 status-related migration, autophagy, senescence, and EMT processes in CD44high/CD166high populations of MFR-surviving cells can reveal new potential targets of NSCLC cell resistance to radiotherapy, opening up an avenue for the development of new modulators radiosensitizing tumor cells while rescuing normal tissue for patients’ therapeutic benefit. This evidence concerns the gene TP53 and neoplasm.